Terms: = Skin cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987
221 results:
1. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract] [Full Text] [Related]
2. Superficial dedifferentiated liposarcoma: A clinicopathologic study.
Bourgeau M; Gandhi JS; Deeb KK; Bahrami A
Hum Pathol; 2024 Mar; 145():63-70. PubMed ID: 38423223
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of The Utility of The Sarcoma DNA Methylation Classifier In Surgical Pathology.
Miettinen M; Abdullaev Z; Turakulov R; Quezado M; Luiña Contreras A; Curcio CA; Rys J; Chlopek M; Lasota J; Aldape KD
Am J Surg Pathol; 2024 Jan; 48(1):112-122. PubMed ID: 37921028
[TBL] [Abstract] [Full Text] [Related]
4. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.
Karimpour M; Totonchi M; Behmanesh M; Montazeri H
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37863651
[TBL] [Abstract] [Full Text] [Related]
5. A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
Miranda J; Vázquez-Blomquist D; Bringas R; Fernandez-de-Cossio J; Palenzuela D; Novoa LI; Bello-Rivero I
BMC Cancer; 2023 Aug; 23(1):806. PubMed ID: 37644431
[TBL] [Abstract] [Full Text] [Related]
6. Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness.
Cismas S; Pasca S; Crudden C; Trocoli Drakensjo I; Suleymanova N; Zhang S; Gebhard B; Song D; Neo S; Shibano T; Smith TJ; Calin GA; Girnita A; Girnita L
Mol Cancer Res; 2023 Dec; 21(12):1288-1302. PubMed ID: 37584671
[TBL] [Abstract] [Full Text] [Related]
7. Genetic Characteristics of Primary Cutaneous Malignant Melanoma in Koreans Compared With Western Populations.
Jang H; Ryu HJ; Kim SK
In Vivo; 2023; 37(2):862-867. PubMed ID: 36881068
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
Huang R; Shen G; Ren Y; Zheng K; Wang J; Shi Y; Yin JC; Qin L; Zhang G; Zhao M; Su X; Li L; Wang F; Shao Y; Liu B; Zou Z
J Transl Med; 2023 Feb; 21(1):78. PubMed ID: 36739402
[TBL] [Abstract] [Full Text] [Related]
9. Cardiac myxoma with atypical cell population mimicking malignancy - a diagnostic pitfall.
Stejskal V; Steiner I; Vobornik M
Cardiovasc Pathol; 2023; 63():107511. PubMed ID: 36462616
[TBL] [Abstract] [Full Text] [Related]
10. In Vitro/In Vivo Translation of Synergistic Combination of mdm2 and MEK Inhibitors in Melanoma Using PBPK/PD Modelling: Part I.
Witkowski J; Polak S; Rogulski Z; Pawelec D
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361773
[TBL] [Abstract] [Full Text] [Related]
11. Superficial GLI1-amplified mesenchymal neoplasms: Expanding the spectrum of an emerging entity which reaches the realm of dermatopathology.
Machado I; Hosler GA; Traves V; Claramunt R; Sanmartín O; Santonja C; Carvajal N; Zazo S; Requena L; Alfonso VS; Domenech EV; Llombart-Bosch A; Bridge JA; Linos K
J Cutan Pathol; 2023 Jun; 50(6):487-499. PubMed ID: 36316249
[TBL] [Abstract] [Full Text] [Related]
12. Radiation-response in primary fibroblasts of long-term survivors of childhood cancer with and without second primary neoplasms: the KiKme study.
Grandt CL; Brackmann LK; Poplawski A; Schwarz H; Hummel-Bartenschlager W; Hankeln T; Kraemer C; Marini F; Zahnreich S; Schmitt I; Drees P; Mirsch J; Grabow D; Schmidberger H; Binder H; Hess M; Galetzka D; Marron M
Mol Med; 2022 Sep; 28(1):105. PubMed ID: 36068491
[TBL] [Abstract] [Full Text] [Related]
13. EIF3B stabilizes PTGS2 expression by counteracting mdm2-mediated ubiquitination to promote the development and progression of malignant melanoma.
Fang P; Han Y; Qu Y; Wang X; Zhang Y; Zhang W; Zhang N; Li G; Ma W
Cancer Sci; 2022 Dec; 113(12):4181-4192. PubMed ID: 36050601
[TBL] [Abstract] [Full Text] [Related]
14. Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature.
Chłopek M; Lasota J; Thompson LDR; Szczepaniak M; Kuźniacka A; Hińcza K; Kubicka K; Kaczorowski M; Newford M; Liu Y; Agaimy A; Biernat W; Durzyńska M; Dziuba I; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kato H; Kopczyński J; Michal M; Michal M; Pęksa R; Prochorec-Sobieszek M; Starzyńska A; Takahashi S; Wasąg B; Kowalik A; Miettinen M
Mod Pathol; 2022 Nov; 35(11):1609-1617. PubMed ID: 35978013
[TBL] [Abstract] [Full Text] [Related]
15. Milademetan is a highly potent mdm2 inhibitor in Merkel cell carcinoma.
Ananthapadmanabhan V; Frost TC; Soroko KM; Knott A; Magliozzi BJ; Gokhale PC; Tirunagaru VG; Doebele RC; DeCaprio JA
JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35801592
[TBL] [Abstract] [Full Text] [Related]
16. Transcription factor YY1 contributes to human melanoma cell growth through modulating the p53 signalling pathway.
Zhou S; Li P; Qin L; Huang S; Dang N
Exp Dermatol; 2022 Oct; 31(10):1563-1578. PubMed ID: 35730240
[TBL] [Abstract] [Full Text] [Related]
17. Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
Moschos SJ; Sandhu S; Lewis KD; Sullivan RJ; Puzanov I; Johnson DB; Henary HA; Wong H; Upreti VV; Long GV; Flaherty KT
Invest New Drugs; 2022 Oct; 40(5):1051-1065. PubMed ID: 35635631
[TBL] [Abstract] [Full Text] [Related]
18. Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of cancer Registries (FRANCIM).
Amadeo B; Penel N; Coindre JM; Ray-Coquard I; Plouvier S; Delafosse P; Bouvier AM; Gallet J; Lacourt A; Galvin A; Coureau G; Monnereau A; Blay JY; Desandes E; Mathoulin-Pélissier S;
Cancer; 2022 Jul; 128(13):2483-2492. PubMed ID: 35385134
[TBL] [Abstract] [Full Text] [Related]
19. The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein.
Hoyos D; Greenbaum B; Levine AJ
Cell Death Differ; 2022 May; 29(5):938-945. PubMed ID: 35383292
[TBL] [Abstract] [Full Text] [Related]
20. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.
Castro MV; Barbero GA; Máscolo P; Ramos R; Quezada MJ; Lopez-Bergami P
Cell Mol Biol Lett; 2022 Mar; 27(1):23. PubMed ID: 35260073
[TBL] [Abstract] [Full Text] [Related]
[Next]
